Mundipharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MUNDIPHARMA, and when can generic versions of MUNDIPHARMA drugs launch?
MUNDIPHARMA has one approved drug.
There are seven US patents protecting MUNDIPHARMA drugs.
There are seventy-five patent family members on MUNDIPHARMA drugs in twenty-four countries.
Summary for Mundipharma
| International Patents: | 75 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Mundipharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 11,712,459 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 9,526,835 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 8,722,619 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 10,702,573 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417-001 | Mar 22, 2023 | RX | Yes | Yes | 11,197,909 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
